Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Delayed]Notice Regarding Basic Agreement on the Transfer of Generic Drug Business
KYORIN Pharma Surges on License Agreement with France's Biodol for Neuropathic Pain Drug Candidate
KYORIN Enters into License Agreement with BIODOL for Novel Neuropathic Pain Treatment
KYORIN Enter into Distribution and Promotion Agreement with Johnson & Johnson for SIRTURO
KYORIN and UBE Enter into License Agreement for Novel Drug Candidates
Notice Regarding the Introduction of a Mandate-Based Corporate Officer System and Changes in Corporate Officers
KYORIN Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 36%, Oct-Dec Ordinary Profit Increases by 2.1 times
KYORIN Receives Regulatory Approval for influenza virus nucleic acid kit, GeneSoC FluAB Detection Kit
Consolidated Financial Results for the Nine Months Ended December 31, 2025 - Supplementary Information
Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Japanese GAAP]
KYORIN and Lunatus Enter into Distribution Agreement for Lasvic Tablets in Nine Middle Eastern Countries
Presentation document (Nov 10, 2025)
[Summary]Consolidated Financial Results for the Six Months Ended September 30, 2025) [Japanese GAAP]
Consolidated Financial Results for Second Quarter (Interim Period) of FY2025 - Supplementary Information
KYORIN Pharma, First Half Ordinary Profit Decreases by 23%, Jul-Sep Ordinary Profit Turns to Loss
KYORIN and Hinge Bio Enter into a Collaboration and License Agreement of HB2198 in Japan for SLE and other diseases
Topline Results from Phase 3 Clinical Study of KRP-R120 for Interstitial Lung Disease
KYORIN Pharma, Apr-Jun (1Q) Ordinary Profit Increases by 85%, Exceeds First Half Plan
Summary of Consolidated Financial Results(For the first quarter ended June 30, 2025) [Japanese GAAP]
Consolidated Financial Results for First Quarter of FY2025 - Supplementary Information